These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38527797)

  • 1. The role of leukocytes in myeloproliferative neoplasm thromboinflammation.
    Liu Y; Wang Y; Huang G; Wu S; Liu X; Chen S; Luo P; Liu C; Zuo X
    J Leukoc Biol; 2024 May; 115(6):1020-1028. PubMed ID: 38527797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
    Marin Oyarzún CP; Heller PG
    Front Immunol; 2019; 10():1373. PubMed ID: 31258539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.
    Hasselbalch HC; Elvers M; Schafer AI
    Blood; 2021 Apr; 137(16):2152-2160. PubMed ID: 33649757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.
    Bhuria V; Baldauf CK; Schraven B; Fischer T
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.
    Reeves BN; Beckman JD
    Curr Hematol Malig Rep; 2021 Jun; 16(3):304-313. PubMed ID: 33876389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms.
    Ferrer-Marín F; Cuenca-Zamora EJ; Guijarro-Carrillo PJ; Teruel-Montoya R
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.
    Ball S; Thein KZ; Maiti A; Nugent K
    J Thromb Thrombolysis; 2018 May; 45(4):516-528. PubMed ID: 29404876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukocyte adhesion and thrombosis.
    Afshar-Kharghan V; Thiagarajan P
    Curr Opin Hematol; 2006 Jan; 13(1):34-9. PubMed ID: 16319685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombosis in myeloproliferative neoplasms.
    Falanga A; Marchetti M
    Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the thrombotic risk in patients with myeloproliferative neoplasms.
    Vianello F; Battisti A; Cella G; Marchetti M; Falanga A
    ScientificWorldJournal; 2011 May; 11():1131-7. PubMed ID: 21623459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombotic disease in the myeloproliferative neoplasms.
    Falanga A; Marchetti M
    Hematology Am Soc Hematol Educ Program; 2012; 2012():571-81. PubMed ID: 23233637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
    Horvat I; Boban A; Zadro R; Antolic MR; Serventi-Seiwerth R; Roncevic P; Radman I; Sertic D; Vodanovic M; Pulanic D; Basic-Kinda S; Durakovic N; Zupancic-Salek S; Vrhovac R; Aurer I; Nemet D; Labar B
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):53-63. PubMed ID: 30301673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms.
    Schafer AI
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):305-324. PubMed ID: 33641871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboinflammation in Therapeutic Medicine.
    Ekdahl KN; Teramura Y; Asif S; Jonsson N; Magnusson PU; Nilsson B
    Adv Exp Med Biol; 2015; 865():3-17. PubMed ID: 26306440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
    Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
    Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
    Sun T; Zhang L
    Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
    Marchetti M; Falanga A
    Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.
    Mihaila RG
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Mar; 161(1):50-53. PubMed ID: 28145534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.